ArticleOncotarget2022

MK256 is a novel CDK8 inhibitor with potent antitumor activity in AML through downregulation of the STAT pathway.

Jen-Chieh Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.